Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer-Reference-Cited by-同舟云学术

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

Published:2011-08-25 Issue:6 Volume:118 Page:1523-1532
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Loupakis Fotios,Cremolini Chiara,Salvatore Lisa,Schirripa Marta,Lonardi Sara,Vaccaro Vanja,Cuppone Federica,Giannarelli Diana,Zagonel Vittorina,Cognetti Francesco,Tortora Giampaolo,Falcone Alfredo,Bria Emilio

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference41 articles.

1. Colorectal cancer;Cunningham;Lancet.,2010

2. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy;Allegra;J Clin Oncol.,2009

3. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer;Hurwitz;Oncologist.,2009

4. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab;Ince;J Natl Cancer Inst.,2005

5. Biomarkers to predict the clinical efficacy of bevacizumab in cancer;Jubb;Lancet Oncol.,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database;British Journal of Cancer;2024-02-24

2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

3. Irinotecan or Oxaliplatin: Which is the First Move for the Mate?;Current Medicinal Chemistry;2021-05-31

4. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream;Cancer Management and Research;2018-11

5. BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies;The Oncologist;2017-06-02